$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn

$hrgn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016622 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.085M	$2.378M	$1.902M
YoY Change	3.43%	25.03%	264.37%
% of Gross Profit
Research & Development	$1.566M	$509.0K	$303.0K
YoY Change	380.37%	67.99%	-35.94%
% of Gross Profit
Depreciation & Amortization	$11.00K	$12.00K	$14.00K
YoY Change	-15.38%	-14.29%	-67.44%
% of Gross Profit
Operating Expenses	$2.651M	$2.887M	$2.205M
YoY Change	92.8%	30.93%	121.61%
Operating Profit	-$2.651M	-$2.887M	-$2.205M
YoY Change	92.8%	30.93%	121.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$37.00K	-$3.000K	$28.00K
YoY Change	23.33%	-110.71%	-76.86%
Pretax Income	-$2.614M	-$2.890M	-$2.177M
YoY Change	94.35%	32.75%	149.08%
Income Tax
% Of Pretax Income
Net Earnings	-$2.614M	-$2.890M	-$2.177M
YoY Change	94.35%	32.75%	149.08%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.19	-$0.24	-$0.20
Diluted Earnings Per Share	-$0.19	-$0.24	-$0.20
COMMON SHARES
Basic Shares Outstanding	13.88M shares	12.21M shares	10.76M
Diluted Shares Outstanding	13.79M shares	12.21M shares	10.76M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.663M	$3.269M	$723.0K
YoY Change	0.5%	352.14%	55.15%
Cash & Equivalents	$2.140M	$3.269M	$3.828M
Short-Term Investments	$2.523M
Other Short-Term Assets	$338.0K	$357.0K	$3.207M
YoY Change	129.93%	-88.87%	632.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.001M	$3.626M	$3.930M
YoY Change	4.47%	-7.74%	324.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.00K	$46.00K	$96.00K
YoY Change	-57.14%	-52.08%	-70.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$62.00K	$544.0K
YoY Change	-64.16%
Total Long-Term Assets	$780.0K	$710.0K	$238.0K
YoY Change	105.8%	198.32%	-27.88%
TOTAL ASSETS
Total Short-Term Assets	$5.001M	$3.626M	$3.930M
Total Long-Term Assets	$780.0K	$710.0K	$238.0K
Total Assets	$5.781M	$4.336M	$4.168M
YoY Change	11.9%	4.03%	231.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$372.0K	$755.0K	$1.273M
YoY Change	-75.18%	-40.69%	1471.6%
Accrued Expenses	$1.569M	$563.0K	$4.153M
YoY Change	227.56%	-86.44%	1158.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.967M	$1.326M	$9.109M
YoY Change	-7.35%	-85.44%	1081.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$18.00K	$21.00K	$30.00K
YoY Change	-18.18%	-30.0%	-34.78%
Total Long-Term Liabilities	$18.00K	$21.00K	$30.00K
YoY Change	-18.18%	-30.0%	-71.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.967M	$1.326M	$9.109M
Total Long-Term Liabilities	$18.00K	$21.00K	$30.00K
Total Liabilities	$1.985M	$1.347M	$9.139M
YoY Change	-7.46%	-85.26%	944.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.50M	-$85.90M	-$79.10M
YoY Change	9.94%	8.6%
Common Stock	$139.0K	$127.0K	$108.0K
YoY Change	19.83%	17.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.796M	-$1.062M	-$4.971M
YoY Change
Total Liabilities & Shareholders Equity	$5.781M	$4.336M	$4.168M
YoY Change	11.9%	4.03%	231.85%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.614M	-$2.890M	-$2.177M
YoY Change	94.35%	32.75%	149.08%
Depreciation, Depletion And Amortization	$11.00K	$12.00K	$14.00K
YoY Change	-15.38%	-14.29%	-67.44%
Cash From Operating Activities	-$1.546M	-$1.013M	-$519.0K
YoY Change	36.21%	95.18%	-7.32%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$9.000K
YoY Change	-125.0%
Acquisitions
YoY Change
Other Investing Activities	-$2.523M
YoY Change
Cash From Investing Activities	-$2.525M	-$9.000K
YoY Change	31462.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.942M	$3.050M	3.055M
YoY Change	46.73%	-0.16%
NET CHANGE
Cash From Operating Activities	-1.546M	-$1.013M	-519.0K
Cash From Investing Activities	-2.525M	-$9.000K
Cash From Financing Activities	2.942M	$3.050M	3.055M
Net Change In Cash	-1.129M	$2.028M	2.536M
YoY Change	-230.97%	-20.03%	-552.86%
FREE CASH FLOW
Cash From Operating Activities	-$1.546M	-$1.013M	-$519.0K
Capital Expenditures	$2.000K	$9.000K
Free Cash Flow	-$1.548M	-$1.022M	-$519.0K
YoY Change	37.36%	96.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13882060	shares
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001563665
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome		usd
CY2022Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment		usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	BSTG	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts		usd
CY2022Q1	BSTG	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment		usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q1	BSTG	Purchases Of Property And Equipment In Accounts Payable Or Accrued Expenses PurchasesOfPropertyAndEquipmentInAccountsPayableOrAccruedExpenses		usd
CY2022Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2022Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023Q1	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember
CY2023Q1	BSTG	Accrued Legal Expenses Current AccruedLegalExpensesCurrent		usd
CY2022Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35853
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BIOSTAGE, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5210462
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	84 October Hill Road, Suite 11
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Holliston
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01746
CY2023Q1	dei	City Area Code CityAreaCode	(774)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	233-7300
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash Cash	3269000	usd
CY2022Q4	us-gaap	Cash Cash	1241000	usd
CY2023Q1	BSTG	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	266000	usd
CY2022Q4	BSTG	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	274000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	91000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	3626000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1594000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	120000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	147000	usd
CY2023Q1	BSTG	Deferred Financing Cost Non Current DeferredFinancingCostNonCurrent	544000	usd
CY2022Q4	BSTG	Deferred Financing Cost Non Current DeferredFinancingCostNonCurrent	610000	usd
CY2023Q1	us-gaap	Assets Assets	4336000	usd
CY2022Q4	us-gaap	Assets Assets	2400000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	755000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	682000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	472000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	582000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1326000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1363000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1347000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1411000	usd
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4051	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4051	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4180	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4180	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4051000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4180000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12716534	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12716534	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12174467	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12174467	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	127000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	122000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84712000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	79698000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85901000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83011000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1062000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3191000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4336000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2400000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	509000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	303000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2378000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1902000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2887000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2205000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2887000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2205000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	29000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2890000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2177000	usd
CY2023Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	80000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2970000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2177000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12206036	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10761861	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3191000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-80000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	209000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3050000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1840000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2890000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1062000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3029000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3029000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	235000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2177000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4971000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4971000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2890000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2177000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1840000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	235000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	12000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	14000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
CY2023Q1	BSTG	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	-66000	usd
CY2023Q1	BSTG	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment	-8000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-193000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	73000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	597000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-110000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	621000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1013000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-519000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3055000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3050000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3050000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3055000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2028000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2536000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1241000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1292000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3269000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3828000	usd
CY2023Q1	BSTG	Purchases Of Property And Equipment In Accounts Payable Or Accrued Expenses PurchasesOfPropertyAndEquipmentInAccountsPayableOrAccruedExpenses	9000	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	80000	usd
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	209000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85900000	usd
CY2023Q1	us-gaap	Cash Cash	3300000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zTcYfg3KuR36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z7aOjtAnzW0b">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The process of preparing condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i/></span></p>
CY2023Q1	BSTG	Accrued Advisory Costs Current AccruedAdvisoryCostsCurrent	337000	usd
CY2022Q4	BSTG	Accrued Advisory Costs Current AccruedAdvisoryCostsCurrent	300000	usd
CY2022Q4	BSTG	Accrued Legal Expenses Current AccruedLegalExpensesCurrent	135000	usd
CY2023Q1	BSTG	Accrued Audit Services Current AccruedAuditServicesCurrent	44000	usd
CY2022Q4	BSTG	Accrued Audit Services Current AccruedAuditServicesCurrent	80000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	83000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	472000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	582000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	5900000	usd
CY2022Q4	BSTG	Percentage Of Litigation Paid PercentageOfLitigationPaid	1	pure
CY2023Q1	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	5900000	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	29000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	120000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	147000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	120000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	147000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	30000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	30000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	30000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	30000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M26D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M13D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1476	pure
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0918	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	82000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	50000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	132000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	120000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2890000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2177000	usd
CY2023Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	80000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2970000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2177000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12206036	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10761861	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3915807	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3986389	shares

Files In Submission

Name	View Source	Status
bstg-20230331_lab.xml	Edgar Link	unprocessable
0001493152-23-016622-index-headers.html	Edgar Link	pending
0001493152-23-016622-index.html	Edgar Link	pending
0001493152-23-016622.txt	Edgar Link	pending
0001493152-23-016622-xbrl.zip	Edgar Link	pending
bstg-20230331.xsd	Edgar Link	pending
bstg-20230331_cal.xml	Edgar Link	unprocessable
bstg-20230331_def.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
bstg-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn

2023 Q2 Form 10-Q Financial Statement

#000149315223016622 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN Harvard Apparatus Regenerative Technology Inc Stock $hrgn

2023 Q2 Form 10-Q Financial Statement

#000149315223016622 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn